Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $296000.0.

  • ImmunoTech's Cash from Investing Activities fell 1137.72% to $296000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 61725.89%. This contributed to the annual value of $4.7 million for FY2024, which is 66562.5% up from last year.
  • As of Q3 2025, ImmunoTech's Cash from Investing Activities stood at $296000.0, which was down 1137.72% from $754000.0 recorded in Q2 2025.
  • ImmunoTech's 5-year Cash from Investing Activities high stood at $3.7 million for Q4 2024, and its period low was -$336000.0 during Q3 2023.
  • Its 3-year average for Cash from Investing Activities is $529272.7, with a median of $296000.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in ImmunoTech's Cash from Investing Activities was 183084.11% (2024), while the steepest drop was 10256.41% (2024).
  • Over the past 3 years, ImmunoTech's Cash from Investing Activities (Quarter) stood at -$214000.0 in 2023, then surged by 1830.84% to $3.7 million in 2024, then plummeted by 92.01% to $296000.0 in 2025.
  • Its Cash from Investing Activities stands at $296000.0 for Q3 2025, versus $754000.0 for Q2 2025 and $898000.0 for Q1 2025.